Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.
Despite the lack of an overall survival benefit the Seal study gives Karyopharm enough to file for Xpovio’s first solid tumour use.
The first of several perioperative Opdivo trials is said to read out positively, reminding the markets of such settings’ importance.
Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.